A B S T R A C T Increased numbers of circulating granulocyte-monocyte precursor cells (CFUc) have been observed in the peripheral blood of man after antineoplastic chemotherapy. We have developed a canine model to study the biologic significance of this phenomenon for hematopoietic reconstitution following hematopoietically lethal exposure to total body irradiation (TBI). After cyclophosphamide administration, a 16-fold expansion of circulating CFUc numbers was observed during the period of rapid leukocyte recovery that occurred after the chemotherapy-induced leukocyte nadir. We had previously noted this association between leukocyte recovery and CFUc expansion in our human studies. After 900 rad TBI hematopoietic reconstitution was attempted with autologous, cryopreserved collections of peripheral blood mononuclear cells obtained either at times of post-cyclophosphamide CFUc expansion (group A, 14 dogs) or without CFUc expansion (group B, 12 dogs). As compared to group B collections, group A collections contained 11-fold more CFUc and were 12.5-fold more potent in fostering hematopoietic recovery after TBI. These results suggest that the expansion of CFUc numbers we observed was accompanied by a similar expansion of more primitive hematopoietic stem cell numbers. We conclude that chemotherapy-induced expansion of circulating CFUc numbers appears to be of substantial import in effecting hematopoietic reconstitution-an observation that may be of significance for further studies of autologous hematopoietic reconstitution in man. INTRODUCTION Hematopoietic stem cells have been observed to circulate in the blood of several mammalian species including man (1) (2) (3) (4) (5) . Moreover, studies in animal models have demonstrated that autologous mononuclear cells collected solely from the peripheral blood are capable of effecting hematopoietic reconstitution after an otherwise hematopoietically lethal insult from cytoreductive drugs or irradiation (6, 7) .
Studies are currently being undertaken in man to define the importance of autologous hematopoietic reconstitution when used in association with intensive antineoplastic therapy (8) . In the allogeneic setting, donors of hematopoietic stem cells will by selection tend to be free of major illness. For these healthy donors the need to collect hematopoietic stem cells by means ofbulk bone marrow collection is unlikely to be a major problem even though such collection is an operative procedure and requires general or regional anesthesia. Even so, the ability to collect hematopoietic stem cells by a less morbid procedure might be ofuse in allogeneic settings for donors who are unwilling to submit to an operative procedure. This point was recently demonstrated by Rich et al. (9) in a case report involving immune reconstitution with allogeneic peripheral blood leukocytes in the setting of adenosine deaminase-deficient severe combined immuno-deficiency. In this report the donor (the patient's father) refused to be a bone marrow donor, but consented to leukopheresis.
In the autologous setting the need for bulk bone marrow collection may prove to be a more limiting problem. Most cancer patients who are judged suitable for intensive therapy with autologous hematopoietic reconstitution will have undergone prior surgery and other forms of antineoplastic therapy. It would therefore be desirable to avoid the additional morbidity of another operative procedure. In addition, as we recently reported (10) , if large portions of the bony pelvis have been exposed to regional radiotherapy, autolo- Unfortunately, to date, efforts in man at effecting autologous hematopoietic reconstitution using cells collected solely from the peripheral blood have been disappointing (11, 12) . One important exception to this statement, however, has been in the setting of chronic phase, chronic myelogenous leukemia. In this setting circulating hematopoietic stem cell numbers, as measured by circulating granulocyte-monocyte precursor cells (CFUc),1 are greatly expanded, and autologous collections of peripheral blood leukocytes have been effective in promoting hematopoietic reconstitution (13) .
Interestingly, expanded levels of circulating CFUc numbers have been transiently observed in man following the administration of antineoplastic therapy consisting of cyclophosphamide (Cytoxan) and doxorubicin (Adriamycin) either alone (14) or in combination with other agents (15) to patients with malignancies other than chronic myelogenous leukemia. However, whether this chemotherapy-associated expansion of circulating CFUc numbers might have biologic significance for hematopoietic reconstitution has been unclear. Consequently, we have developed a canine model for studying the impact of cyclophosphamideinduced expansion of circulating CFUc numbers on the reconstitutive potency of collections of peripheral blood mononuclear cells. The impetus for the study reported here stemmed directly from our observations in man that chemotherapy-induced expansion of circulating CFUc numbers occurred to a median level of sevenfold in 85% of patients studied during induction chemotherapy for extensive small cell carcinoma of the lung (15) .
METHODS
This study utilized a canine model specifically designed to study hematopoietic reconstitution. The details of this model with respect to animal selection, care, irradiation, postirradiation supportive care, and criteria for engraftment have been described (16, 17) . The model utilizes a hematopoietically lethal dose of total body irradiation (TBI) (900 rad midplane dose at 9 rad/min) followed by supportive care with parenteral fluids, antibiotics, and platelets. Gastrointestinal and other nonhematopoietic toxicity is mild, and there are no deaths related to gastrointestinal toxicity. Dogs 1 Abbreviations used in this paper: CFUc, circulating granulocyte-monocyte precursor cells; TBI, total body irradiation.
failing to achieve hematopoietic reconstitution die from neutropenia and sepsis.
Collection of peripheral blood mononuclear leukocytes was performed utilizing a continuous flow blood cell separator (American Instrument Co., Inc., Silver Spring, Md.). Circulatory access was obtained via a left-sided, jugulocarotid, arteriovenous shunt, maintained for as long as 7 d with daily heparin flushing. During cell collection, blood flow rate through these shunts to the cell separator was maintained at 40-50 ml/min. The bowl speed of the cell separator was maintained at 1,000 rpm. Leukocyte collections containing 3.0-5.0 g/100 ml hemoglobin were obtained at flow rates of 3-4 ml/min and harvested into 600-ml plastic transfer packs containing 13-15 ml of acid citrate dextrose-National Institutes of Health (NIH) solution A. During collection anticoagulation was maintained with heparin.
After cell collection had been completed, shunts were ligated, allowed to clot, and removed 21 d later. The resulting neck wound was irrigated with antibiotic solution and allowed to heal for an additional 1-2 wk.
14 dogs (group A) were given intravenous cyclophosphamide (16 mg/kg) on each of 2 d 1 wk apart (days 0 and 7) in order to produce expansion of circulating CFUc numbers. This dose and timing were based on clinical observations in patients (15) and preliminary experiments in dogs. Dogs receiving cyclophosphamide underwent shunt insertion on day 10 or 13 after the initial cyclophosphamide dose, and cell collection was performed on days [14] [15] [16] . Twelve dogs (group B) had collections obtained without cyclophosphamide pretreatment. All dogs studied were healthy male foxhounds of comparable age (8-12 mo) and weight (group A, mean weight = 31.1+0.7 kg; group B, mean weight = 29.1+0.7 kg, P > 0.10).
Parenteral antibiotics were used prophylactically while shunts were in place, during cyclophosphamide-associated myelosuppression, and during wound healing after shunt removal. Ampicillin and gentamicin were given twice daily in doses of 50 mg/kg and 3.0 mg/kg, respectively.
Samples of blood and bone marrow for CFUc assay were obtained in sterile syringes containing 200-300 U of preservative-free heparin. Aliquots of peripheral blood cell collections were also analyzed for CFUc growth.
Following collection, cells were cryopreserved in 10% dimethyl sulfoxide as described (16, 17) , and the frozen preparations were immersed in liquid nitrogen (-196°C) until needed for reinfusion. Time from cell collection to cell infusion (following TBI) averaged 7 wk. After TBI, dogs were maintained with parenteral fluids, antibiotics, and platelets (transfused for thrombocytopenic bleeding or prophylactically at a count of 20,000/gl or less). Before use all routine blood products were irradiated to 2,500 rad. Blood counts were obtained daily until death or full hematopoietic recovery occurred.
CFUc were plated in 0.3% agar using techniques described from this laboratory (12) with the following modifications: erythrocytes were removed from both blood and bone marrow using dextran sedimentation (0.15 ml of 3% Dextran [223,000 mol wt]/ml of sample) at 37°C for 15-20 min followed by lysis of residual erythrocytes by ammonium chloride-potassium lysing reagent obtained through the National Institutes of Health media room. Cultures were set up in supplemented McCoy's media containing 15% fetal calf serum (Gibco Laboratories, Grand Island Biological Company, Grand Island, N. Y.) (18) and 8% (vol/vol) plasma collected from a lethally irradiated dog 10 d after 900 rad TBI and 4% (vol/vol) human placental conditioned media (19) . These latter two reagents were added just before final plating. A measured inoculum of cell suspension containing 1 x 106 peripheral blood mono-nuclear cells and <2.5 x 106 granulocytes (20) were plated in a final volume of 1 ml in 35-mm Petri plates. Cultures were incubated for 7 d at 370C in a fully humidified ambient atmosphere containing 7.5% C02, and colonies containing a minimum of 15 cells (20) 
RESULTS
Amplification of peripheral blood CFUc levels during post-cyclophosphamide leukocyte recovery.
As shown in Tables I and II, (15) . Mean leukocyte and platelet nadirs in group A dogs were, respectively, 870+170 and 37,000+7,000/,ul. As shown in Fig. 1 , leukocyte nadir typically occurred on day 10 after the administration of cyclophosphamide and was promptly followed by a period of rapid leukocyte recovery between days 13 and 17.
Serial measurements of blood and bone marrow CFUc levels were made on days 7 and 13-16 in four dogs and on days 13-17 in four dogs. Day 7 measurements were made prior to administering the second (day 7) dose of cyclophosphamide. These preliminary experiments were undertaken to document whether the association between chemotherapy-induced ex- dogs (Table I) . This difference was a direct result ofthe myelosuppression that followed cyclophosphamide administration of group A dogs. Nevertheless, these differences did not hamper cell collection from the group A dogs and, as shown in Table I , comparable numbers of leukocytes and mononuclear leukocytes were collected from both groups. Collection was well tolerated, without mortality, in both groups. Immediately after cell collection, hemoglobin, leukocyte, and platelet counts were substantially lower in group A dogs (Table I ), frequently to "clinically" significant levels, and platelet and erythrocyte transfusions were given prophylactically or because ofthrombocytopenic bleeding from puncture wounds to a number of group A dogs. These results show that peripheral blood stem cell collection was possible and reasonably well tolerated in all animals studied, even those with cyclophosphamide-induced suppression of peripheral blood counts. In addition, they also suggest that the myelosuppression observed in this setting did not impair collection ofmononuclear leukocytes. This observation is important because hematopoietic stem cells are, morphologically, mononuclear leukocytes (21) .
CFUc content of cell collections was strikingly increased in the group A dogs. As shown in Table II five), but this difference was not statistically significant (P = 0.20, two-sided t test). Figure 4 relates rate of hematopoietic recovery (days to 1,000 leukocytes/ mm3) to CFUc dose. Linear regression analysis yielded an R value of 0.77 and seemed to provide a reasonable fit of the observed data, suggesting correlation between rate of hematopoietic recovery and CFUc dose. Subsequently, analysis with Spearman's Rank Correlation confirmed significant association between CFUc dose and rate of hematopoietic recovery (P < 0.01).
As shown by the data in Fig. 2 4 .0 x 108 mononuclear cells/kg).
Our CFUc values are also consistent with those provided in these same two studies, both in terms of levels in the peripheral blood prior to treatment and in terms of doses associated with survival.
These results also suggest that with proper attention to post collection blood counts, especially hemoglobin and platelet levels, large numbers of peripheral blood mononuclear cells and circulating hematopoietic stem cells can be safely collected after cyclophosphamide administration in spite of associated, transient myelosuppression. After cell collection, acute hematopoietic recovery continues in an uninterrupted manner.
In conclusion, these results suggest that observed expansion of circulating CFUc numbers in man following nonintensive, systemic chemotherapy (14, 15) may permit collection of circulating hematopoietic stem cells in numbers adequate to effectively promote hematopoietic reconstitution. Such a result would be consistent with current studies in patients with chronic myelogenous leukemia (13) , and would be a major step forward in developing further clinical applications for autologous hematopoietic reconstitution.
